Showing results (21-30 of 275) with videos related to
Sort By:
Pageof 28
Hematology/Oncology Clinics of North America|April 1, 1991
Hematologic effects of AIDS therapiesJ M Pluda, H Mitsuya, R YarchoanThe Journal of Clinical Investigation|August 1, 1986
Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virusR Yarchoan, R R Redfield, S BroderJournal of Biological Regulators and Homeostatic Agents|April 14, 2000
HIV therapy in the post-eradication eraS Vella, L PalmisanoExpert Opinion on Investigational Drugs|November 4, 2000
HIV eradication revisitedS Vella, L PalmisanoClinical Pharmacokinetics|April 16, 1998
Saquinavir. Clinical pharmacology and efficacyS Vella, M FloridiaPrincess Takamatsu Symposia|January 1, 1984
Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitroH Mitsuya, S Matsushita, R Yarchoan, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 1, 1991
Targeted therapy of human immunodeficiency virus-related diseaseH Mitsuya, R Yarchoan, S Kageyama, et al.Kroc Foundation Series|January 1, 1985
Defective specific antiinfluenza virus antibody production in vitro by lymphocytes from patients with ataxia-telangiectasiaR Yarchoan, C C Kurman, D L NelsonHematology/Oncology Clinics of North America|October 1, 1996
AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approachesJ E Karp, J M Pluda, R YarchoanCancer Research|September 1, 1985
Implications of the discovery of HTLV-III for the treatment of AIDSR Yarchoan, H Mitsuya, S Matsushita, et al.Pageof 28